SS
KYMR icon

Steve Schonfeld’s Kymera Therapeutics KYMR Stock Holding History

Steve Schonfeld’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,582
Closed -$1.05M – 2816
2026
Q1 		$1.05M Buy
+12,582
New +$996K 0.01% 1068
2025
Q4 		– Sell
-39,746
Closed -$2.25M – 2331
2025
Q3 		$2.25M Sell
39,746
-19,178
-33% -$865K 0.01% 973
2025
Q2 		$2.57M Buy
58,924
+10,764
+22% +$371K 0.02% 845
2025
Q1 		$1.32M Sell
48,160
-167,320
-78% -$6.1M 0.01% 1165
2024
Q4 		$8.67M Buy
215,480
+36,294
+20% +$1.64M 0.05% 336
2024
Q3 		$8.48M Sell
179,186
-110,277
-38% -$4.87M 0.06% 347
2024
Q2 		$8.64M Sell
289,463
-90,979
-24% -$3.15M 0.06% 390
2024
Q1 		$15.3M Sell
380,442
-57,191
-13% -$2.05M 0.1% 238
2023
Q4 		$11.1M Buy
+437,633
New +$7.83M 0.07% 316
2023
Q1 		– Sell
-17,400
Closed -$434K – 2373
2022
Q4 		$434K Buy
+17,400
New +$464K ﹤0.01% 1605
2020
Q4 		– Sell
-6,672
Closed -$216K – 1727
2020
Q3 		$216K Buy
+6,672
New +$204K ﹤0.01% 1200

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Steve Schonfeld's KYMR Position: Q2 2026 in Review

Steve Schonfeld sold out of Kymera Therapeutics (KYMR) in Q2 2026, closing a stake of 12,582 shares — an estimated $1.05M sold.

Steve Schonfeld first reported a position in KYMR in Q3 2020 and held it in 11 quarters. The position peaked at $15.3M in Q1 2024. 273 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Steve Schonfeld reported no remaining Kymera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Steve Schonfeld sold 12,582 Kymera Therapeutics shares in Q2 2026, an estimated $1.05M.
  • Steve Schonfeld first reported a position in Kymera Therapeutics in Q3 2020 and held it in 11 quarters.
  • Steve Schonfeld's Kymera Therapeutics position peaked at $15.3M in Q1 2024.
  • 273 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.